Healthcare Realty Trust Incorporated Common Stock (HR)

FairStock Score: 53/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a value investor, but because it is a REIT, I set aside EPS-based tools. The company owns 579 medical outpatient properties, 33.6 million square feet across 28 states, with an enterprise value around $11.1 billion. That is a real asset base, and medical office buildings near hospital campuses can have sticky tenants and defensive demand. Still, the filed figures show persistent losses: net income was -$278.3 million in FY2023, -$654.5 million in FY2024, -$246.1 million in FY2025, and -$43.5 million in fiscal Q2 2026 (quarter ended 2026-06-30). Revenue in that fiscal Q2 2026 was $8.0 million, while fiscal Q1 2026 revenue was $7.7 million. Those numbers are hard to reconcile with the stated size, and FFO/AFFO—the right REIT measures—are not in my data. So I lean on dividend yield, leverage, revenue trend and price-to-book. At the 2026-10-13 close of $17.22, P/B is 1.40; D/E is 1.03; Altman Z is 0.76, which suggests financial stress. The 5.26% dividend yield looks attractive, but a 2.3% FCF yield, -1.92% ROE, 0.86% ROCE, and negative P/E (-66.23) do not point to a bargain. FairStock calls it a TURNAROUND—a loss in the latest year after earlier profits. Beta of 0.81 may mean lower volatility, but I would need FFO/AFFO and debt maturities before treating this as a sound value proposition.

In plain English: Healthcare Realty Trust owns medical office buildings, mostly near hospitals. The business is not in strong shape right now: it has been reporting losses, has a lot of debt, and the dividend is high but may be hard to sustain. At $17.22, the price looks mixed rather than clearly cheap or expensive based on the numbers given.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer